Picture supply: Getty Pictures
Kromek Group (LSE: KMK) is an AIM-listed 10.7p penny inventory with a £72.6m market-cap. The UK-based group develops radiation detection gear for medical imaging, nuclear websites and safety screening.
It serves primarily the home and US market, primarily supplying cadmium zinc telluride-based detectors.
Do you have to purchase Kromek Group Plc shares immediately?
Earlier than you resolve, please take a second to assessment this report first. Regardless of ongoing uncertainties from Trump’s tariffs to world conflicts, Mark Rogers and his group consider many UK shares nonetheless commerce at substantial reductions, providing savvy buyers loads of potential alternatives to study.
That is why this might be a perfect time to safe this beneficial analysis – Mark’s analysts have scoured the markets to disclose 5 of his favorite long-term ‘Buys’. Please, do not make any massive selections earlier than seeing them.
That’s a comparatively area of interest market, which could be each advantagous and problematic. Whereas it’s unlikely to face stiff competitors, demand for its merchandise may drop sharply if situations change.
However for now, it appears to be doing very properly. Let’s take a better look.
Lofty progress expectations
The share value has soared 103% up to now 12 months, pushed largely by sturdy H1 outcomes masking the six months to 31 October 2025.
And analysts following the inventory don’t suppose it’s finished. They count on additional progress, with an bold 12-month goal of twenty-two.5p — a 106% rise!
However is it real looking to count on the shares to double in worth once more by subsequent April?
Earlier than getting too excited, I made a decision to take a better look.
In demand
What I like about Kromek is that it truly has pretty first rate earnings visibility for a penny inventory. Its near-term income pipeline is substantial, with offers in place value upward of $20m for 2026.
This momentum’s pushed by expanded distribution in 39 new nations throughout Europe, the Center East and Asia.
In H1 2026, it reported £15m in income — up from £3.7m — with administration guiding for £60m by 2030. That’s an bold goal, however is it backed by proof of prevailing demand?
These notable orders and contract wins appear to recommend so:
- £4.8m orders globally.
- A $37.5m cope with Siemens Healthineers.
- A £1.7m, four-year Radiological Nuclear Detection Framework with the UK MoD.
- Extra nuclear safety orders from UK/Europe, US, Japan, and Canada value £2.9m.
- Multi-year bio-security contracts within the US.
So it’s a worthwhile, rising enterprise that seems to be in excessive demand. What’s the catch?
Dangers
Micro-cap shares all the time face greater danger than bigger firms, and Komek’s no stranger to that. Provide chain points and reliance on debt are key challenges that the group has struggled with up to now.
It nonetheless carries £4.62m in debt and wishes to keep up excessive money circulate to maintain working. Any important contract loss or delayed order may throw it off monitor. Plus, penny shares are thinly traded, which provides liquidity danger for shareholders.
Nonetheless, with £56.88m in fairness and a return on fairness (ROE) of 25%, I wouldn’t say it’s struggling.
My verdict
Penny shares all the time require a bit extra religion than larger-caps, with the excessive reward potential coming with a giant dollop of danger. As a rule, assessing them appears like attempting to see at the hours of darkness. However for Kromek Group, its forecast value progress’s backed by real-world use instances and regular demand.
Apart from a gradual medical imaging orderbook, the rising menace of nuclear instability within the Center East will possible enhance demand.
Like every micro-cap, it’s not one thing to go all in on. However with rising demand and promising forecasts, it’s value contemplating as a small allocation.
